<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00908934</url>
  </required_header>
  <id_info>
    <org_study_id>D1520C00004</org_study_id>
    <secondary_id>EudraCT Number: 2009-010554-35</secondary_id>
    <nct_id>NCT00908934</nct_id>
  </id_info>
  <brief_title>AZD9056 Relative Bioavailability Study</brief_title>
  <official_title>An Open-label, Randomized, 2 Cohort, 2 Period Crossover Study to Assess the Relative Bioavailability of the Phase III to the Phase IIb Formulation of AZD9056 in Healthy Male and Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aims of this study are to compare the blood levels achieved with a new formulation of
      AZD9056 to an existing formulation of AZD9056 used in previous studies.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative bioavailability of AZD9056 using PK variables Cmax and AUC</measure>
    <time_frame>For each study period, intensive sampling occasions on day 1: half hourly after dosing until 4 hours, then 4,6,8 and 12 hours post dose, with once daily sampling on days 2 to 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Descriptive PK parameters for AZD9056 using PK variables (tmax, AUC(0-t), t1/2, CL/F and Vz/F)</measure>
    <time_frame>For each study period, intensive sampling occasions on day 1: half hourly after dosing until 4 hours, then 4,6,8 and 12 hours post dose, with once daily sampling on days 2 to 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety variables (adverse events, safety lab, blood pressure, pulse, ECG)</measure>
    <time_frame>Frequent sampling occasions throughout the study period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 or 400 mg AZD9056, Test formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 or 400 mg AZD9056, Reference formulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD9056 formulation Phase III 50 mg (T)</intervention_name>
    <description>Given as 50 mg tablet (T)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD9056 formulation Phase IIb 50 mg (R)</intervention_name>
    <description>Given as 50 mg tablet (R)</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD9056 formulation Phase III 200 mg (T)</intervention_name>
    <description>Given as 400 mg (2 x 200 mg tablet (T))</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD9056 formulation Phase IIb 200mg (R)</intervention_name>
    <description>Given as 400 mg (2 x 200 mg tablet (R))</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of informed consent prior to any study-specific procedures

          -  Healthy Volunteers, Females should not be of childbearing potential

          -  BMI between 18 and 30 kg/m2

        Exclusion Criteria:

          -  Clinically significant ECG abnormality suggestive of underlying cardiovascular disease

          -  A history or presence of GI, hepatic or renal disease or other condition known to
             interfere with the absorption, distribution, metabolism and excretion of drugs

          -  Known or suspected drug or alcohol abuse or positive DOA test
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Layton</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca R&amp;D, Alderley Park, UK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Simon Constable</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICON Development Solutions, Manchester, UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2009</study_first_submitted>
  <study_first_submitted_qc>May 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2009</study_first_posted>
  <last_update_submitted>July 22, 2009</last_update_submitted>
  <last_update_submitted_qc>July 22, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 23, 2009</last_update_posted>
  <keyword>Relative Bioavailability</keyword>
  <keyword>AZD9056</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

